Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(17)
BIOLOGICAL(6)
DRUG(3)
OTHER(1)
Laboratory Biomarker Analysis
5 trials
phase_1phase_1_2
roswell-park-cancer-institute
Sirolimus
3 trials
phase_1
roswell-park-cancer-institute
ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine
2 trials
phase_1phase_1_2
roswell-park-cancer-institute
sargramostim
2 trials
phase_1
roswell-park-cancer-institute
Pharmacological Study
2 trials
phase_1phase_1_2
roswell-park-cancer-institute
enzyme-linked immunosorbent assay
1 trial
phase_1
roswell-park-cancer-institute
NY-ESO-1 peptide vaccine
1 trial
phase_1
roswell-park-cancer-institute
decitabine
1 trial
phase_1
roswell-park-cancer-institute

+10 more interventions

18 unique interventions4 categories

Analytics

Trial Phases

Phase 15
Phase 21

Trial Status

Completed3
Other2

Role Distribution

Principal Investigator5
PI Rate100%

Activity Timeline

Clinical Trials (5)

NCT02833506Phase 1Withdrawn
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma+18 more
PrincipalinvestigatorStart date: 2017-12-08
NCT01536054Phase 1Completed
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Recurrent Fallopian Tube CancerRecurrent Ovarian Epithelial CancerRecurrent Primary Peritoneal Cavity Cancer+21 more
PrincipalinvestigatorStart date: 2012-08-20
NCT01522820Phase 1Completed
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Anaplastic AstrocytomaAnaplastic OligoastrocytomaAnaplastic Oligodendroglioma+62 more
Principalinvestigator
NCT01673217Phase 1Completed
Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Recurrent Fallopian Tube CancerRecurrent Ovarian Epithelial CancerRecurrent Primary Peritoneal Cavity Cancer
Principalinvestigator
NCT01982487Phase 1/2Withdrawn
Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission
Recurrent Fallopian Tube CancerRecurrent Ovarian Epithelial CancerRecurrent Primary Peritoneal Cavity Cancer+30 more
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Stanislaw R. Burzynski, MD, PhD

Burzynski Research Institute

Related
62 trials

Shared therapeutic areas:

Stage IV Prostate CancerAnaplastic AstrocytomaSarcoma+1 more
Similarity Score1%

Norman Wolmark, MD

NSABP Foundation Inc

Related
54 trials

Shared therapeutic areas:

Stage IB Breast CancerStage IIB Breast CancerStage IIIA Breast Cancer+1 more

Worked with same sponsors:

Eisai Inc.National Cancer Institute (NCI)
Similarity Score1%

Ingrid Mayer, MD

Vanderbilt-Ingram Cancer Center

Related
13 trials

Shared therapeutic areas:

Stage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

Rahul Aggarwal, MD

University of California, San Francisco

Related
22 trials

Shared therapeutic areas:

Metastatic Prostate CarcinomaRecurrent Prostate CarcinomaStage IV Prostate Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

Steven A Rosenberg, M.D.

National Cancer Institute (NCI)

Related
32 trials

Shared therapeutic areas:

GlioblastomaMetastatic Renal Cell Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

Xiaoli Lan, PhD

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Related
16 trials

Shared therapeutic areas:

SarcomaGlioblastoma
Similarity Score1%

Maryam Fouladi, MD

Nationwide Children's Hospital

Related
10 trials

Shared therapeutic areas:

Anaplastic AstrocytomaGlioblastoma
Similarity Score1%

Zhenfeng Zhang, MD, PhD

Second Affiliated Hospital of Guangzhou Medical University

Related
21 trials

Shared therapeutic areas:

SarcomaStage IV Ovarian Cancer
Similarity Score1%

Michael B Gill

Power Life Sciences Inc.

Related
105 trials

Shared therapeutic areas:

GlioblastomaSarcoma
Similarity Score1%

Brigitte C Widemann, M.D.

National Cancer Institute (NCI)

Related
19 trials

Shared therapeutic areas:

Sarcoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score0%

Publications (0)

No publications found for this investigator.

Clinical Trials (5)

Showing 5 of 5 trials

NCT02833506Phase 1PrincipalInvestigator

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma+18 more
Withdrawn
NCT01536054Phase 1PrincipalInvestigator

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Fallopian Tube CancerRecurrent Ovarian Epithelial CancerRecurrent Primary Peritoneal Cavity Cancer+21 more
Completed
NCT01522820Phase 1PrincipalInvestigator

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Anaplastic AstrocytomaAnaplastic OligoastrocytomaAnaplastic Oligodendroglioma+62 more
Completed
NCT01673217Phase 1PrincipalInvestigator

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Recurrent Fallopian Tube CancerRecurrent Ovarian Epithelial CancerRecurrent Primary Peritoneal Cavity Cancer
Completed
NCT01982487Phase 1/2PrincipalInvestigator

Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission

Recurrent Fallopian Tube CancerRecurrent Ovarian Epithelial CancerRecurrent Primary Peritoneal Cavity Cancer+30 more
Withdrawn

All 5 trials loaded